Following the closure of the Phase III ALTITUDE trial, researchers have published the first detailed figures showing the risk of...
Novartis announced that the CHMP has concluded the risk-benefit review of Rasilez (aliskiren) and combination products containing aliskiren and confirmed...
Tekturna/Rasilez (aliskiren) from Novartis has failed to show a benefit in target organ protection which has resulted in the early...
The AQUARIUS study shows that Tekturna/Rasilez (aliskiren), from Novartis, neither improves nor slows the progression of coronary atherosclerosis when given...